+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 13Years +
All Genders
ID04771572

Phase 1 Study of Oral LP-118 to Assess Safety and Effects in Adults with Relapsed or Refractory Blood Cancers

Led by Newave Pharmaceutical Inc · Updated on 2026-05-05

100

Participants Needed

8

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying LP-118, a new oral drug, in adults with various types of relapsed or refractory blood cancers, including leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma. This Phase 1 trial aims to find the safest dose, understand how the drug behaves in the body, and explore early signs of effectiveness. The study includes patients with specific tumor risk levels and prior treatment histories to evaluate safety and tolerability. The trial has two main parts a dose-escalation phase where participants receive increasing doses of LP-118 once daily to find the maximum tolerated dose or recommended Phase 2 dose, and a dose-expansion phase to further assess safety, drug behavior, and effectiveness at selected doses. Dosing starts at 20 mg and may increase to as high as 800 mg daily. The study groups are organized based on cancer types and tumor lysis risk, with dose adjustments guided by patient response and side effects. Participants will be monitored closely throughout treatment cycles, each lasting 28 days. Researchers will regularly measure drug levels in the blood, track safety and side effects, and assess cancer responses using disease-specific criteria. Key outcomes include determining the maximum tolerated dose, pharmacokinetics of LP-118, progression-free survival, duration of response, and overall survival. The study expects participation to continue through multiple cycles as appropriate, with ongoing safety and efficacy evaluations.

CONDITIONS

Brief Title

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Research Team

A

Anna Chen, MD, PhD

S

Stephen Anthony, DO

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here